MedTrace Logo

A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

NCT07717814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-07-21

No results posted yet for this study

Summary

The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in participants living with overweight or obesity.

Conditions

  • Overweight and Obesity

Interventions

DRUG

AMG 133 (frozen liquid)

AMG 133 will be administered as a SC injection.

DRUG

AMG 133 (liquid)

AMG 133 will be administered as a SC injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2025-05-22
Completion
2025-06-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07717814 on ClinicalTrials.gov